MED27 plays a tumor‐promoting role in breast cancer progression by targeting KLF4

Abstract

AbstractThe mediator complex usually cooperates with transcription factors to be involved in RNA polymerase II‐mediated gene transcription. As one component of this complex, MED27 has been reported in our previous studies to promote thyroid cancer and melanoma progression. However, the precise function of MED27 in breast cancer development remains poorly understood. Here, we found that MED27 was more highly expressed in breast cancer samples than in normal tissues, especially in triple‐negative breast cancer, and its expression level was elevated with the increase in pathological stage. MED27 knockdown in triple‐negative breast cancer cells inhibited cancer cell metastasis and stemness maintenance, which was accompanied by downregulation of the expression of EMT‐ and stem traits‐associated proteins, and vice versa in non‐triple‐negative breast cancer. Furthermore, MED27 knockdown sensitized breast cancer cells to epirubicin treatment by inducing cellular apoptosis and reducing tumorsphere‐forming ability. Based on RNA‐seq, we identified KLF4 as the possible downstream target of MED27. KLF4 overexpression reversed the MED27 silencing‐mediated arrest of cellular metastasis and stemness maintenance capacity in breast cancer in vitro and in vivo. Mechanistically, MED27 transcriptionally regulated KLF4 by binding to its promoter region at positions −156 to +177. Collectively, our study not only demonstrated the tumor‐promoting role of MED27 in breast cancer progression by transcriptionally targeting KLF4, but also suggested the possibility of developing the MED27/KLF4 signaling axis as a potential therapeutic target in breast cancer.